Penetratin Decoration Increases RNAi Silencing Effects of Polymeric Carriers
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide This study reports the development of a polymeric carrier for pulmonary siRNA delivery via inhalation. Poly(α,β-N-(2-hydroxyethyl)- d, l -asparamide) (PHEA) was first functionalized with divinyl sulfone (DV) to form PHEA-VS, enabling controlled grafting of 1,2-bis(3-aminopropylamino)ethane (bAPAE, of about ∼25 mol %) and poly(2-methyl-2-oxazoline) (PMeOx, of about ∼5 mol %). The resulting PHEA-VS- g -(PMeOx;bAPAE) copolymer contained protonable amines for efficient siRNA complexation. Potentiometric titration confirmed strong buffering capacity, while fluorescence studies indicated pH-responsive membrane interaction, suggesting improved endosomal escape. Polyplexes formed starting from a polymer/siRNA ratio of 5, with diameters below 40 nm, showing stability in mucins and pulmonary surfactant and protection against RNase degradation. Surface decoration with the cell-penetrating peptide penetratin (Pen) via a terminal alkyne on PMeOx enhanced cellular uptake and siRNA release. Biocompatibility tests on 16-HBE cells showed viability over 80% at high polymer concentrations. Functional assays in MDA-MB-231-LUC cells demonstrated effective gene silencing, particularly at a polymer/siRNA ratio of 5. Combined with the favorable aerosolization properties of aqueous dispersions, these results highlight PHEA-VS- g -(PMeOx;bAPAE) as a versatile platform for pulmonary siRNA delivery, offering stability, biocompatibility, and targeted intracellular release for potential treatment of respiratory diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Lab of Biocompatible Polymers, Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, Palermo 90123, Italy
Funding
NextGenerationEU
References (50)
Show source-provided references
1. 10.1016/j.jconrel.2020.11.00510.1016/j.jconrel.2020.11.005 ↗
2. 10.1016/j.mtbio.2024.10096610.1016/j.mtbio.2024.100966 ↗
3. Merkel O. M. · 2014 · 112
4. 10.1016/j.cbi.2022.11004810.1016/j.cbi.2022.110048 ↗
5. 10.1016/j.addr.2019.05.00410.1016/j.addr.2019.05.004 ↗
6. 10.1186/s12951-023-02147-z10.1186/s12951-023-02147-z ↗
7. 10.1016/j.ijpharm.2017.01.03410.1016/j.ijpharm.2017.01.034 ↗
8. 10.1016/j.jconrel.2023.09.00110.1016/j.jconrel.2023.09.001 ↗
9. 10.1016/j.ejps.2023.10658010.1016/j.ejps.2023.106580 ↗
10. 10.1016/j.addr.2017.08.01010.1016/j.addr.2017.08.010 ↗
11. 10.1016/j.addr.2022.11430910.1016/j.addr.2022.114309 ↗
12. 10.1002/anie.20090160710.1002/anie.200901607 ↗
13. 10.1002/marc.20120045310.1002/marc.201200453 ↗
14. 10.1016/j.biomaterials.2018.05.02210.1016/j.biomaterials.2018.05.022 ↗
15. 10.1016/j.jconrel.2007.02.01510.1016/j.jconrel.2007.02.015 ↗
16. 10.1021/bc200049d10.1021/bc200049d ↗
17. 10.1021/mp400681n10.1021/mp400681n ↗
18. 10.1134/S000629792311011110.1134/S0006297923110111 ↗
19. Tuttolomondo M. · 2021 · 2282 · 353
20. 10.1016/j.bbrc.2014.01.10710.1016/j.bbrc.2014.01.107 ↗
21. Falato L. · 2021 · 2282 · 329
22. 10.1021/acsami.3c1447210.1021/acsami.3c14472 ↗
23. 10.1016/j.actbio.2015.11.02910.1016/j.actbio.2015.11.029 ↗
24. 10.1021/acs.bioconjchem.0c0007810.1021/acs.bioconjchem.0c00078 ↗
25. 10.1016/j.ijpharm.2012.07.02910.1016/j.ijpharm.2012.07.029 ↗
26. 10.1016/j.jconrel.2018.02.01610.1016/j.jconrel.2018.02.016 ↗
27. 10.1016/j.jconrel.2018.07.00110.1016/j.jconrel.2018.07.001 ↗
28. 10.1016/j.jconrel.2008.07.00110.1016/j.jconrel.2008.07.001 ↗
29. 10.1021/acs.biomac.4c0038710.1021/acs.biomac.4c00387 ↗
30. 10.1016/j.nano.2021.10245110.1016/j.nano.2021.102451 ↗
31. 10.1007/s13346-021-01102-510.1007/s13346-021-01102-5 ↗
32. 10.1002/mabi.20070016510.1002/mabi.200700165 ↗
33. 10.1016/j.colsurfb.2016.11.02510.1016/j.colsurfb.2016.11.025 ↗
34. 10.1007/s00396010049210.1007/s003960100492 ↗
35. 10.1039/C5NR03178H10.1039/C5NR03178H ↗
36. 10.1007/s13204-022-02508-410.1007/s13204-022-02508-4 ↗
37. 10.1002/mabi.20210002510.1002/mabi.202100025 ↗
38. 10.1021/jp109151s10.1021/jp109151s ↗
39. 10.1016/j.addr.2019.08.00410.1016/j.addr.2019.08.004 ↗
40. 10.1038/s41565-021-00858-810.1038/s41565-021-00858-8 ↗
41. 10.1016/j.jconrel.2007.07.00610.1016/j.jconrel.2007.07.006 ↗
42. 10.1007/s11095-014-1598-610.1007/s11095-014-1598-6 ↗
43. De Levie R. · 200110.1017/CBO9780511808265 ↗
44. 10.1021/ja804561g10.1021/ja804561g ↗
45. 10.1039/C4CC09859E10.1039/C4CC09859E ↗
46. 10.1016/j.colsurfb.2023.11332710.1016/j.colsurfb.2023.113327 ↗
47. 10.1016/j.addr.2023.11514410.1016/j.addr.2023.115144 ↗
48. 10.1021/jacs.7b0537610.1021/jacs.7b05376 ↗
49. 10.1021/acs.biomac.7b0048110.1021/acs.biomac.7b00481 ↗
50. 10.1002/advs.20210367610.1002/advs.202103676 ↗